AAA (ADVANCED ACCELERATOR APPLICATIONS) - Axess PR
Loading

From 2016 through to 2017, Axess PR managed all of the Strategic Communications, Corporate Communications, Health Communication and Financial Communications for Advanced Accelerator Applications.

Our team successfully managed a Reputation & Crisis Management episode. We also opened a fruitful discussion with two Italian Oncology Thought Leaders (Prof. Massimo Falconi and Prof. Gianfranco Delle Fave). 

Results

    Axess PR supported Advanced Accelerator Applications in addressing and managing successfully, professionally and with specific skills a case of Crisis Management in 2016 in Meldola, Italy which is home of one of the company’s production plants.

Client

AAA

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical group that develops, produces and markets Nuclear Molecular Medicine (MNM). AAA is a European leader in the production and marketing of radiopharmaceuticals PET and SPECT in the field of Molecular Nuclear Diagnostics (MND).

These radio-pharmaceutical medicines are mostly employed in oncological clinical diagnosis, cardiology and neurology. AAA’s main therapeutic product candidate, Lutathera, is a new MNM solution that is being developed to treat neuroendocrine tumors to the small intestine, or NET, a significant unmet medical need.

There are 20 AAA centers divided between production plants and , R&D, that produce both diagnostic and therapeutic Nuclear Molecular Medicine (MNM), and more than 440 employees in 13 countries ( Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Portugal, United Kingdom, Spain, United Stated and Switzerland).

LET'S START WORKING TOGETHER

TELL US ABOUT YOUR PROJECT

Contact us